Q4 revenue consensus $91.77M. Preliminary fourth-quarter and full-year 2024 Rezdiffra net sales ranges of $100 million to $103 million and $177 million to $180 million, respectively. Preliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 million. More than 11,800 patients on Rezdifrra as of year-end 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Oppenheimer starts Sagimet with Outperform on ‘underappreciated opportunity’
- Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities
- Madrigal Pharmaceuticals price target raised to $400 from $350 at Oppenheimer
- Paulson takes new stake in Southwestern Energy, exits AngloGold Ashanti
Questions or Comments about the article? Write to editor@tipranks.com